We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




PCR Market Rises to USD3.5 Billion for 2015

By LabMedica International staff writers
Posted on 04 Jul 2016
The total PCR (polymerase chain reaction) technologies market was valued at about USD3.5 billion for 2015, up from USD3.2 billion in 2013, according to Kalorama Information (New York, NY, USA), a healthcare market research company.

PCR is a biochemical technology in molecular biology that is used to amplify a single copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. More...
PCR technologies are being increasingly used for medical testing, particularly for diagnosing bacterial and infectious diseases, detecting antibiotic resistance, and for cancer exploration of mutations and detection of genetic abnormalities. These technologies, particularly quantitative PCR (qPCR) and digital PCR (dPCR), hold great promise for expanding diagnostic applications.

qPCR is mainly used for DNA sequencing and gene expression in stem cell research, oncology and genetic disease research, pathogen detection and infectious disease research, and plant sciences research. It is also utilized in forensic science, food and safety applications, genetically modified organisms (GMO) testing, and detection of genetic abnormalities and cancer mutations. The coming years are expected to witness an expansion in qPCR-based diagnostic tests.

On the other hand, dPCR provides absolute measurement of copies and is the next logical step in PCR evolution. dPCR partitions sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. The technology provides greatly improved sensitivity in the detection of rare mutations and sequences, and is likely to become increasingly important with the evolution of clinical applications.

“qPCR has established itself as the workhorse in the research laboratory,” said Bruce Carlson, Publisher of Kalorama Information. “But dPCR’s potential is greater in diagnostic applications due to its sensitivity, precision, robustness, and reproducibility.”

The US and European PCR technology markets have been witnessing intensifying competition, resulting in increasing participation in other regions like Asia and Latin America. Among the number of companies in the PCR technology market are large multi-product companies like Thermo Fisher Scientific (Waltham, MA, USA), Roche Holding AG (Basel, Switzerland), and Abbott (Abbot Park, IL, USA), as well as small niche developers such as RainDance Technologies (Billerica, MA, USA).

Related Links:
Kalorama Information
Thermo Fisher Scientific
Roche
Abbott
RainDance Technologies

New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR System
OnePCR
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.